Efficacy of Jihwangeumja (Dihuang Yinzi) on cognitive function and activities of daily living in patients with Alzheimer disease

Abstract

Background: This systematic review protocol describes the methods proposed to evaluate the efficacy and safety of Jihwangeumja in patients with Alzheimer disease. Methods: The following databases, PubMed, EMBASE, CENTRAL, Cumulative Index to Nursing and Allied Health Literature, China National Knowledge Infrastructure, National Digital Science Library, Korean Information Service System, and Korean Medical Database will be searched for relevant publications without language or publication status restrictions. Search terms will be based on “Alzheimer” for participants and “Jihwangeumja” or “Dihuang Yinzi” for interventions. Two researchers will independently extract the study data from the included studies and only randomized controlled trials will be included. The risk of bias will also be assessed independently by 2 researchers using the Cochrane risk of bias tool. We will use RevMan software random-effects and fixed-effect models for the assessment of heterogeneity and data synthesis. Any changes in the plan for documenting significant protocol amendments will require the researchers to have a revision agreement and register the international prospective register of systematic review modification. Results: The treatment effect and safety will be measured by meta-analysis and the quality of the included studies will be reviewed. Conclusion: This systematic review will provide evidence regarding the efficacy and safety of Jihwangeumja. Ethics and dissemination: Ethical approval is not required because individual patient data will not be included in this paper. The study findings will be disseminated through conference presentations. OSF Registration DOI: 10.17605/OSF.IO/HXA58.

Dihuang-Yinzi Alleviates Cognition Deficits via Targeting Energy-Related Metabolism in an Alzheimer Mouse Model as Demonstrated by Integration of Metabolomics and Network Pharmacology

“…(Hu et al, 2009;Qiu et al, 2016;Lee et al, 2021). The effectiveness of DHYZ has been proven via clinical verification for a long time (Lee et al, 2021). In the present study, we investigated and evaluated the effects of DHYZ on spatial memory and cognition of 2× Tg-AD mice by MWM.…”

“…Dihuang-Yinzi is a well-accepted traditional Chinese herbal prescription which is widely used for the treatment of various aging-related diseases and neurological deficits, such as AD, Parkinson's disease, amyotrophic lateral sclerosis, arteriosclerosis, aging-related stroke, etc. (Hu et al, 2009;Qiu et al, 2016;Lee et al, 2021). The effectiveness of DHYZ has been proven via clinical verification for a long time (Lee et al, 2021).…”

“…(Table 1). Clinically, DHYZ has been used in the treatment of neurodegenerative diseases, including AD, for a long time (Lee et al, 2021). In recent years, many studies demonstrated that DHYZ exhibits neuroprotective functions in a variety of neurological diseases (Hu et al, 2009;Qiu et al, 2016).…”

“…Furthermore, DHYZ improved the cognition of ischemic mice by depressing the expression of extracellular signal-regulated protein kinase (ERK) and synaptophysin (SYP) (Hu et al, 2009). A study based on a meta-analysis shows that DHYZ can significantly improve the cognitive function and daily activities of AD patients (Lee et al, 2021). Our previous studies have shown that DHYZ can ameliorate the learning and memory impairments of rat and mouse model of AD by depressing mitochondrial impairments and improving energy production (Ma et al, 2012;Huang et al, 2018;Yan et al, 2018).…”

Neuroprotective effects of Morinda officinalis How.: Anti-inflammatory and antioxidant roles in Alzheimer’s disease

“…In traditional medicine, aging is believed to be closely associated with kidney deficiency. Because DY promotes kidney function, it may exhibit therapeutic effects in AD, in which aging is the main etiological factor ( Lee et al, 2021 ). Moreover, DY has been shown to improve the cognition and energy metabolism of mice by protecting against mitochondrial injury ( Zhu et al, 2014 ).…”